Liposuction relieved lipoedema pain where conservative therapy did not

Design

Multicentre, randomised (2:1), assessor-masked controlled trial

Population

410 women with stage I–III lipoedema and leg pain of at least 4/10, at 11 German centres

Primary outcome

At least a 2-point reduction in patient-reported leg pain at 12 months

Effect

68% (190/278) vs 8% (10/132); odds ratio 26.2 (95% CI 13.1–52.5). Serious adverse events 8% vs 3%

Lipoedema is a painful disorder of subcutaneous adipose tissue that overwhelmingly affects women, and it has been managed for decades with complex decongestive therapy on thin evidence. Eleven German centres enrolled 453 women with stage I to III lipoedema and leg pain of at least 4 on a 0–10 scale, gave everyone conservative therapy for up to seven months, then randomised 410 of them 2:1 to liposuction or continued conservative therapy. Assessors were masked by applying patches to every patient's legs.

At 12 months, 190 of 278 (68%) in the liposuction arm had achieved the primary endpoint of at least a two-point fall in leg pain, against 10 of 132 (8%) on conservative therapy (odds ratio 26.2, 95% CI 13.1–52.5, P < 0.0001). Missing assessments were counted as failures, which is the conservative way to handle them. Quality-of-life secondary endpoints moved the same way.

The cost side is real. Adverse events occurred in 47% of the liposuction group against 21% of the conservative group, and serious adverse events in 8% versus 3%. A 36-month follow-up is ongoing. That is the shape of the conversation to have: a large, clearly demonstrated symptomatic benefit against a roughly one-in-twelve chance of a serious complication.

• Take a woman describing disproportionate, painful leg fat that does not respond to weight loss seriously — lipoedema is commonly mistaken for obesity or lymphoedema.
• Offer conservative therapy first, as the trial did, and judge the response before considering surgery.
• Quote both numbers when discussing liposuction: 68% reached meaningful pain relief, and 8% had a serious adverse event.
• Note that durability beyond 12 months is not yet known — the long-term follow-up is still running.
• In India this is almost entirely a private, self-funded procedure, and surgeon experience with lipoedema specifically varies widely.

Why it matters

A condition managed on habit rather than evidence now has a randomised answer, and it points to surgery.

Don't overread it

The primary endpoint was patient-reported pain in a trial where patients knew which treatment they received.

The statistics, in plain English

An odds ratio of 26.2 is unusually large, and it partly reflects how rarely the control arm succeeded — 8% is close to the floor, which inflates a ratio. The absolute difference, 68% versus 8%, is the honest way to state the benefit. Assessor masking was attempted with patches, but patients knew whether they had had surgery, and the endpoint was patient-reported pain, so some of the effect will be expectation.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.